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Lung cancer is one of the most common cancers worldwide,and the overall incidence continues to increase. Despite
advances in treatment, the overall 5-year survival is still
approximately 10% to 15%. A better therapeutic impact
depends on the ability to diagnose the cancer in an early
stage.
When the suspicion of lung cancer is raised, a com-
puted tomographic (CT) scan is necessary.
A number of screening studies of lung cancer have been
published.1–4 In these studies, the sub-centimeter, non-calci-
fied lesions were identified in 30% to 60% of cases. However,
only 1% to 3 % of these lesions turned out to be malignant.
Thus, the final diagnosis can not rely on CT alone; invasive
procedures are needed.
Imaging-guided fine-needle aspirations have an overall
accuracy of 64% to 100% for detecting malignancy,5,6 and
bronchoscopy-guided biopsies of centrally located lesions
have an accuracy of 70% to 90%.7 Follow-up CT is therefore
still needed in a number of patients.
Recently, new techniques for detecting lung cancer
have become available. It seems that refinement of the CT
technique with high-resolution CT (HRCT) in subgroups of
lesions increases the specificity solely by morphological char-
acterization, thereby reducing the need for invasive proce-
dures.8,9 Thus, Furuya et al.8 found an accuracy for malig-
nancy of more than 93% by using specific morphologic
criteria on HRCT.
Nuclear medicine methods have also emerged. The
high level of somatostatin receptor expression on various
tumor cells has provided the molecular basis for the success-
ful use of radiolabeled somatostatin analogs as tumor tracers.
Somatostatin-receptor scintigraphy is a well documented
method of diagnosing neuroendocrine tumors10 and has been
used since 1989. Furthermore, it has been shown to be able to
detect both small cell lung cancer (SCLC), which possesses
neuroendocrine characteristics, as well as non-small cell lung
cancer (NSCLC).11 Until recently, an 111Indium-labeled so-
matostatin analogue, octreotide, was the only tracer used for
imaging. However, in 2000, a 99mTc-labeled somatostatin
analogue depreotide became commercially available for scin-
tigraphic imaging of suspected malignant tumors in the lung.
So far, studies have found that 99mTc-depreotide has a
high sensitivity for detecting lung cancer (89% to 100 %) but
low specificity (43% to 73%).12–19
18F-fluoro-2-deoxy-D-glukose (FDG) positron emis-
sion tomography (PET) has an integral role in the manage-
ment of many oncological tumors, including lung tumors, in
regard to characterization and staging.20 However, compared
with single emission computerized tomography (SPECT)
scanners, PET scanners are still more costly, and availability
is still rather limited, even in developed countries.
The aim of this study was to assess the diagnostic
impact of HRCT and 99mTc-depreotide separately and in
combination among patients with pulmonary lesions demon-
strated by conventional CT.
PATIENTS AND METHODS
Patients
Fifty-seven consecutive patients (32 women, 25 men)
with an average age of 63 years (range, 38 to 82 years) were
included in the study. All patients were referred from the
primary sector to the Department of Pulmonology because of
suspicion of lung cancer. The inclusion criteria were based on
the CT detection of one or more peripheral lung lesions that
could not be reached by bronchoscopy. Supplementary
HRCT of the lesions and a 99mTc-depreotide imaging was
then performed. The final diagnosis was based on fine-
needle aspiration, bronchoalveolar lavage (BAL) or brush
biopsies, core biopsies, biopsies of the surgical removed
tissue, chest radiograph, or CT follow-up as per normal
protocols (Table 1).
Fluoroscopic-guided trans-thoracic fine-needle aspira-
tion (TTFNA) was performed up to three times to increase the
sensitivity for malignant lesions. In malignant lesions, the
fluoroscopic- and ultrasonic- (US) guided TTFNA was suf-
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ficient for the final diagnosis for 25 patients; the procedure
was performed once for 20 patients, twice for three patients,
and three times for two patients. The final malignant diagno-
sis was the result of histological examination of the surgically
removed tissue for 21 patients.
For benign lesions, TTFNA was performed once for
eight patients, two times for three patients, and three times for
two patients. For 12 patients, a benign diagnosis was obtained
by chest radiography or CT follow-up. In all 12 patients the
lesions decreased in size or disappeared. One patient under-
went surgery despite the fact that a TTFNA showed inflam-
matory disease because of an extreme malignant presentation
at CT. The final diagnosis was inflammatory disease.
The results of the 99mTc-depreotide scintigraphy were
not included in the definitive diagnostic decision-making
process.
CT/HRCT Scan
CT examinations were performed by using a Philips
MX8000IDT 16-row CT scanner (Best, Netherlands). The
usual protocol in the management of patients with suspected
lung cancer was used (collimation 16 1.5 mm, RI  1 mm,
RW  2 mm, 120 kV, 150 mAs, rotation time 0.75 seconds,
pitch 1.5). Iodixanol (Visipaque 270 mg/ml; GE Healthcare,
Oslo, Norway) 2 ml/kg body weight was injected at 4 ml/sec.
A soft reconstruction algorithm was used. The lungs were
scanned after a 35-second delay after contrast medium was
injected. The upper abdomen was scanned after a 65-second
delay during the portal venous phase. If an infiltrate in the
lung was detected, additional HRCT slices through the infil-
trate were performed: collimation 0.75 mm, RI  0.5 mm,
RW  1 mm, rotation time 0.75 seconds, 120 kV, 150 mAs.
99mTc-depreotide Imaging
Vials of 47-g depreotide (NeoSpect) were provided
by GE Healthcare. 99mTc-depreotide was prepared, and qual-
ity control was performed according to the manufacturing
manual. 99mTc-depreotide was injected within 5 hours after
preparation.
No special preparations for the patients were required.
SPECT of the chest was performed 2 to 4 hours after injection
with a dual-headed gamma camera. SPECT was performed at
120 angles using a 128  128 matrix with 30 seconds per
angle. Image reconstruction was performed using an iterative
algorithm without attenuation correction. Images were post-
filtered with a low-pass filter (cut-off 0.30, order number 5.0).
Tumor to non-tumor activity ratios were calculated.
Regions of interest were drawn around the tumor on the
transaxial tomograms that showed the highest tumor uptake.
A region of the same pixel size was drawn in the same area
in the contralateral normal lung, and the total counts obtained
in the two areas were divided.
Image Interpretation
The CT/HRCT was evaluated by two radiologists in
collaboration, and lesions were classified into one of three
categories: high, intermediate, or low probability of malig-
nancy.8,9 High probability of malignancy included HRCT
findings as spiculation, ragged configuration and a halo
around the lesion combined with other signs, including feed-
ing vessels and pleural retraction. Low probability of malig-
nancy included HRCT morphologic findings as benign calci-
fications, fat content, well defined margins, or obvious signs
of infection on CT. All other lesions were defined as having
an intermediate probability of malignancy.
Two nuclear medicine physicians in collaboration eval-
uated the 99mTc-depreotide scan visually. The images were
graded positive if there was an increase in uptake activity in
the area of the CT-detected lesions. Only a written descrip-
tion of the location of the lesions was known before these
assessments.
After grading, the 99mTc-depreotide images and the
CT/HRCT scan were compared directly by the two radiolo-
gists and the two nuclear medicine physicians to confirm that
the lesions on both scans were indeed located in the same
area. Software for image fusion was not available.
Statistical Analysis
Sensitivity, specificity, positive and negative predictive
values, and mean values ( standard deviation) were com-
puted in the standard manner.
Ethics
Before the study, ethical approval was obtained from
the Regional Ethics Committee, and written consent was
obtained from all patients included in the study.
TABLE 1. Frequency of methods used for final diagnosis
30 malignant lesions in 29 patients
29 benign lesions in 28 patients
Bi-planar fluoroscopic-guided TTFNA
US-guided TTFNA
Bi-planar fluoroscopic-guided TTCB
US-guided TTCB
Thoracoscopic-guided core biopsy
Brush biopsy
Brocheoalveolar lavage
Bi-planar fluoroscopic-guided TTFNA
Bi-planar fluoroscopic-guided TTCB
US-guided TTCB
Thoracoscopic-guided core biopsy
Follow-up
24
1
1
1
1
1
1
13
2
1
1
1
2
TTFNA, trans-thoracic fine-needle-aspiration; US, ultrasonic; TTCB, Trans-thoracic core biopsy.
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RESULTS
A total of 59 lesions were detected by CT. The average
size of the lesions was 31 mm (range, 5 to 74 mm), and the
median size was 25 mm. Thirteen lesions were 15 mm, and
46 were15 mm. Thirty lesions were malignant and 29 were
benign. The overall prevalence of a malignant lesion was
0.51. In the two groups of lesions (15 mm and 15 mm),
the prevalence was 23% and 59%, respectively (Table 2).
HRCT
The findings of HRCT compared with the final diag-
nosis are presented in Table 3. HRCT classified 26 lesions
(44%) as having a high probability of malignancy and 13
(22%) as having low probability, of which one was false-
negative. Twenty (34%) were classified as having an inter-
mediate probability of malignancy. If the lesions in this latter
group are considered to be malignant, as would be the case in
a clinical setting, the sensitivity of HRCT is 97%, the spec-
ificity is 41%, the negative and positive predictive values are
92% and 63%, respectively. The four HRCT false-positive
cases represented one atelectasis, supported by the TTFNA.
The lesion disappeared on follow-up CT 2 months later, after
treatment with antibiotics and physiotherapy. The three other
cases represented inflammation/abscess that disappeared on
follow-up CT 2, 2, and 3 months later, respectively, after
treatment with antibiotics.
99mTc-Depreotide
The results for 99mTc-depreotide compared with the
final diagnosis are presented in Table 4.
99mTc-depreotide did not result in any false negatives,
but 14 false-positive lesions were seen (sensitivity 100%,
specificity 52%). The positive and negative predictive value
of 99mTc-depreotide was 68% and 100%, respectively. The
false-positive results were the result of infection/inflamma-
tion in four cases; fibrosis in four cases; atelectasis, tubercu-
losis, and a hamartoma in one case each; and three had
changes that resolved over time.
Table 5 summarizes the definitive diagnosis for the
true-positive, false-positive, and true-negative lesions.
A detailed description of the two size groups of lesions
(15 mm or 15 mm) is presented in Table 2 and is related
to SPECT sensitivity, specificity, accuracy, and prevalence of
malignancy. The smallest lesion detected by 99mTc-dep-
reotide was 10 mm.
The mean tumor-to-non-tumor ratio was 2.1 0.8 (1.2;
4.2). The mean ratio in the true-positive group was 2.2  0.7
(1.3; 4.2), which is very similar to the mean ratio in the
false-positive group of 2.0  0.8 (1.3; 3.6).
HRCT and 99mTc-Depreotide
The findings of 99mTc-depreotide compared with the
final diagnosis in each of the three groups: high, intermediate,
and low probability of malignancy classified by HRCT are
presented in Table 6.
HRCT showed a high probability of lung cancer in 26
lesions, 22 of which were malignant (positive predictive
value of 84%). Of the four benign cases, only one was
99mTc-depreotide–negative.
HRCT showed a low probability of lung cancer in 13
lesions. One was erroneously classified as benign (negative
TABLE 2. Prevalence of malignancy, sensitivity, specificity,
and accuracy of 99mTc-depreotide
Size Prevalence Sensitivity Specificity Accuracy
15 mm 3/13 (23%) 3/3 (100%) 7/10 (70%) 10/13 (77%)
15 mm 27/46 (59%) 27/27 (100%) 8/19 (42%) 35/46 (76%)
TABLE 3. Findings of HRCT compared with the final
diagnosis
HRCT Malign Benign
High 22 4 26
Intermediate 7 13 20
Low 1 12 13
30 29 59
TABLE 4. Findings of 99mTc-depreotide compared with the
final diagnosis
99mTc-depreotide Malign Benign
Positive 30 14 44
Negative 0 15 15
30 29 59
TABLE 5. Final diagnosis for the true-positive, false-positive,
and true-negative lesions at 99mTc-depreotide scan
Final diagnosis Lesions
True-positive
NSCLC 3
Adenocarcinoma 18
Squamous cell carcinoma 7
SCLC 2
Total 30
False-positive
Non-malignant 3
Fibrosis 4
Inflammation 2
Infection 2
Atelectasis 1
Tuberculosis 1
Hamartoma 1
Total 14
True-negative
Non-malignant 11
Hamartoma 2
Fibrosis 1
Inflammation 1
Total 15
NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.
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predictive value of 92%). 99mTc-depreotide correctly detected
this lesion but also had five false-positive results.
HRCT showed an intermediate probability of lung
cancer in 20 lesions, seven of which were malignant and 13
of which were benign. Seven of the 13 benign lesions were
99mTc-depreotide–negative.
Figure 1 shows an example of 99mTc-depreotide in a
patient with an adenocarcinoma.
DISCUSSION
The main findings of the present study demonstrate that
99mTc-depreotide after HRCT has considerable diagnostic
value in the group of patients with lung lesions classified as
having an intermediate probability of malignancy.
HRCT alone seems to be relatively accurate in the
group of lesions that could be classified as either high or low
probability of malignancy with a positive predictive value of
84% in the first group and a negative predictive value of 92%
in the second group. However, as many as one third of the
lesions could not be classified in one of these groups by
HRCT; they were classified as indeterminate lesions, which is
the group that constitute the major clinical challenge.
The sensitivity of 99mTc-depreotide for detecting lung
cancer was high because all malignant tumors in the study
showed an increased uptake of 99mTc-depreotide. There were
no false-negative results. A negative 99mTc-depreotide there-
fore indicates that further investigations, such as invasive
procedures or control CT scans, are unnecessary. However, in
other studies, false-negative findings were report-
ed,12,14,15,17,18 and a large-scale study is necessary before a
final recommendation can be made. The number of false-
positive results was high. These overall results are confirmed
by other investigators 12–15,17.
Despite its low specificity, 99mTc-depreotide can prob-
ably reduce the need for further diagnostic procedures by
35% in the group of indeterminate lesions classified by
HRCT.
The 14 false-positive 99mTc-depreotide scans repre-
sented inflammatory or infectious diseases, fibrosis, one gran-
uloma, atelectasis, and one hamartoma (see Table 5). Two
hamartomas were 99mTc-depreotide–negative. The positive
findings in granulomas and in inflammatory and infectious
diseases are probably caused by an increased expression of
somatostatin receptors on the surface of activated lympho-
cytes.21 High uptake in fibrosis, atelectasis, and hamartomas
has previously been reported,12,17,18,22 but the reason is still
unclear, unless it can be explained by some infiltration of
activated lymphocytes in the area surrounding these lesions.
To our knowledge, no one has investigated the presence of
somatostatin receptors in hamartomas and fibrotic tissue.
Like Baath et al.13 and Grewal et al.,17 we found no
relationship between histology and tumor-to-non-tumor ratio,
which means that a high intensity in uptake is no indication
of malignancy in our study. However, we did not correct for
a partial volume effect, which might cause distortion of the
scintigraphic findings depending on the size of the lesions.
Such correction was made by Plaschcinska et al.,23 who did
find a significant difference between the semi-quantitative
uptake in malignant and benign pulmonary nodules.
The mean size of lesions was 31 mm, and the median
size was 25 mm. It is a well known phenomenon that the risk
of malignancy increases in correlation with the size of the
lesion.24 Accordingly, we found a higher prevalence of can-
cer when the size of the lesions was 15 mm, whereas the
specificity was higher in the group of lesions of15 mm (see
Table 2).
Because it has not yet been proven that 99mTc-dep-
reotide is able to detect lesions 10 mm, such lesions should
be followed using CT.
In vitro studies have shown somatostatin receptor ex-
pression on the surface of SCLC,25 but the reason for the
accumulation of somatostatin analogues in NSCLC is not yet
fully understood. Several studies have endeavored to estab-
lish the presence of somatostatin receptors in NSCLC in
vitro, but the results have so far been inconsistent. Thus,
some studies have failed to demonstrate the presence of
somatostatin receptors in NSCLC in vitro,10,11,25 whereas
others have succeeded in demonstrating the presence of
TABLE 6. The 99mTc-depreotide results compared with the
final diagnosis in A the 26 lesions with high probability of
malignancy, B the 20 lesions with intermediate probability,
and C the 13 lesions with low probability of malignancy
classified by HRCT
A. 99mTc-depreotide Malign Benign
Positive 22 3 25
Negative 0 1 1
22 4 26
B. 99mTc-depreotide Malign Benign
Positive 7 6 13
Negative 0 7 7
7 13 20
C. 99mTc-depreotide Malign Benign
Positive 1 5 6
Negative 0 7 7
1 12 13
FIGURE 1. A 64-year-old woman with increased uptake in
the left upper lobe on the 99mTc-depreotide scan. Histology
showed an adenocarcinoma.
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somatostatin receptors. O’Byrne et al. 26 found specific bind-
ing sites for an octapeptide analogue of somatostatin, RC-
160, in cells of three squamous cell carcinomas but given the
mixed histology of the tumors, the binding may be to tissue
other than the tumor cells (i.e., lymphocytes). The results
from other studies have shown that different tumor cells
express a high degree of heterogeneity including somatostatin
receptor subtypes.27–29 In conclusion, the reason for the
accumulation of somatostatin analogues in NSCLC in vivo
seems to be the presence of somatostatin receptors in tumor
cells, although the studies vary considerably in both design
and outcome. The subtype most consistently reported is
subtype 2. It is likely that expression of receptors in peritu-
moral vessels and activated lymphocytes affects the results in
the study containing resected tumors masses.21,30 The subject
is reviewed by Plachcinska et al.,31 who reached almost the
same conclusion.
Blum et al.12 had three false-negative results that rep-
resented adenocarcinomas, all 20 mm in size. High back-
ground activity adjacent to the tumors was mentioned as a
probable explanation for not detecting these tumors. The
same explanation was given for the only false-negative ade-
nocarcinoma in the study by Baath et al.17 Kahn et al.14 had
seven false-negative results, two of which were bronchoal-
veolar carcinomas; the remaining five were of unknown
histological origin. The size of the false negatives, except
one, was 20 mm. The size of the two bronchoalveolar
carcinomas was not specified. Martins et al.15 reported on one
false negative and a bronchoalveolar carcinoma, 10 mm in
size. One other bronchoalveolar carcinoma, 30 mm in size, in
the same patient was correctly identified, as were all bron-
choalveolar carcinomas in two other patients as well. In
general, there seem to be three reasons for false-negative
results: small tumors, tumors adjacent to areas with high
activity uptake, and bronchoalveolar carcinomas. The first
two were to be expected, whereas the results in bronchoal-
veolar carcinomas are more confusing because well differen-
tiated tumors are known to express an increased number of
somatostatin receptors.32 Perhaps the number of false-nega-
tive bronchoalveolar carcinomas can be explained by their
small size rather than the histology.
Two studies have compared 99mTc-depreotide with 18F-
FDG PET in evaluating pulmonary nodules.14,18 Kahn et al.
found similar sensitivity but a higher specificity with 18F-
FDG PET. Sensitivity and specificity with 18F-FDG PET
were 96 % and 71%, respectively, which is in compliance
with the results of other studies.33–35 Halley et al. found
18F-FDG PET to be more sensitive but not more specific than
99mTc-depreotide in the diagnosis of lung cancer of any size.
The false-negative results of 18F-FDG PET were found in
patients with small foci (10 mm) or highly differentiated
tumors such as bronchoalveolar carcinomas.33–35 The false-
positive results were mainly the result of uptake in granulo-
mas and processes with inflammation or infection.
Several studies have claimed the superiority of 18F-
FDG PET compared with CT in the staging of patients with
lung cancer.33–35 However, 18F-FDG PET, as well as 99mTc-
depreotide, is to some extent incorrect regarding T-staging
and the determination of the exact anatomic localization. In
this regard, image fusion using combined scanners
(SPECT/CT or PET/CT) seem promising.36 Only one study14
has compared 99mTc-depreotide and 18F-FDG PET with re-
gard to staging. No significant difference between the two
modalities was found, and the study also concluded that none
of these investigations can be used for staging. In this study,
we did not evaluate the uptake in the mediastinal lymph
nodes.
CONCLUSION
The sensitivity and negative predictive value of 99mTc-
depreotide was 100% in patients with CT-verified pulmonary
lesions. HRCT alone was reliable in the group of patients
classified as having high or low probability of malignancy.
However, HRCT classified one third of the patients as having
an intermediate probability of malignancy. In this group, the
diagnostic value of 99mTc-depreotide after HRCT seem to
contribute to a clinical algorithm in which patients with
lesions indeterminate on HRCT but negative on 99mTc-dep-
reotide do not need further invasive investigations or fol-
low-up examinations. However, further studies are needed
before a change in clinical strategy can be recommended,
especially among patients with small lesions. As the avail-
ability of PET increases, comparative studies between 99mTc-
depreotide and 18F-FDG PET are needed as well.
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